Alivus Life Sciences Limited, formerly Glenmark Life Sciences, is set to increase its investments in research and development as part of its strategic transition under the new corporate identity.
The company’s leadership, including Managing Director and Chief Executive Officer Yasir Rawjee, outlined their growth plans, which emphasize high-value opportunities, geographic expansion, and improved operational efficiency.
Strategic Focus on Growth and Expansion
Rawjee confirmed that Alivus Life Sciences will continue its focus on high-value opportunities while diversifying into new geographical markets.
“As we invest more into the business, we aim to build new levers to drive future growth,” Rawjee stated.
In addition to these efforts, Alivus plans to establish its own state-of-the-art research and development facility within the next 18 months.
Evolving Strategy Post-Rebranding
As for rebranding, Rawjee explained that past investments primarily aimed at increasing capacity to support the company’s business growth.
He also highlighted the oncology platform introduced two and a half years ago as a significant exception.
Moving forward, the company is shifting its focus to developing new platforms that will fuel future growth.
Some teams have already prepared the platforms for implementation.
Ownership Shift and Continued Growth
In September 2023, Glenmark Pharmaceuticals reached a major milestone in its history. The company sold a 75% stake in Glenmark Life Sciences to Nirma Ltd for ₹5,651 crore.
The sale marked a turning point in the company’s restructuring process.
Alivus Life Sciences’ growth can be attributed to its strong performance across various segments. These include both the former parent company, Glenmark Pharmaceuticals (GPL), and non-GPL segments.
Notably, markets in India, Europe, Japan, and the rest of the world have made significant contributions to its success.
As reported by newsonprojects.com, Alivus Life Sciences has these strategies in place. The company is poised to continue expanding and innovating in the coming years.
